Development of latanoprost-loaded biodegradable nanosheet as a new drug delivery system for glaucoma

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 8, 2013, Pages 5629-5637

  Kashiwagi, Kenji ^a   Ito, Keisuke ^b   Haniuda, Hiroki ^b   Ohtsubo, Shinya ^b   Takeoka, Shinji ^b  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b WASEDA UNIVERSITY   (Japan)

Author keywords

Chitosan; Drug delivery system; Glaucoma; Latanoprost; Nanosheet; Sodium alginate

Indexed keywords

LATANOPROST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIODEGRADABLE IMPLANT; BIODEGRADABLE NANOSHEET; BLINKING; CONTROLLED STUDY; DRUG DELIVERY DEVICE; DRUG RELEASE; ENZYME IMMUNOASSAY; EYE IRRITATION; EYE MOVEMENT; GLAUCOMA; HISTOLOGY; HYPEREMIA; INTRAOCULAR PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; SCRATCHING;

CHITOSAN; DRUG DELIVERY SYSTEM; GLAUCOMA; LATANOPROST; NANOSHEET; SODIUM ALGINATE;

ABSORBABLE IMPLANTS; ALGINATES; ANIMALS; ANTIHYPERTENSIVE AGENTS; AQUEOUS HUMOR; BEHAVIOR, ANIMAL; CHITOSAN; CORNEA; DRUG DELIVERY SYSTEMS; GLAUCOMA; GLUCURONIC ACID; HEXURONIC ACIDS; INTRAOCULAR PRESSURE; NANOSTRUCTURES; PROSTAGLANDINS F, SYNTHETIC; RABBITS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84882794336     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-9513     Document Type: Article

References (28)

1. McCarty CA, Mukesh BN, Kitchner TE, et al. Intraocular pressure response to medication in a clinical setting: the Marshfield Clinic Personalized Medicine Research Project. J Glaucoma. 2008;17:372-377.
2. Djafari F, Lesk MR, Harasymowycz PJ, Desjardins D, Lachaine J. Determinants of adherence to glaucoma medical therapy in a long-term patient population. J Glaucoma. 2009;18:238-243.
3. Robin AL, Novack GD, Covert DW, Crockett RS, Marcic TS. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol. 2007;144: 533-540.
4. Okeke CO, Quigley HA, Jampel HD, et al. Adherence with topical glaucoma medication monitored electronically the Travatan Dosing Aid study. Ophthalmology. 2009;116:191-199.
5. Vanelli M, Pedan A, Liu N, Hoar J, Messier D, Kiarsis K. The role of patient inexperience in medication discontinuation: a retrospective analysis of medication nonpersistence in seven chronic illnesses. Clin Ther. 2009;31:2628-2652.
6. Stone JL, Robin AL, Novack GD, Covert DW, Cagle GD. An objective evaluation of eyedrop instillation in patients with glaucoma. Arch Ophthalmol. 2009;127:732-736.
7. Dietlein TS, Jordan JF, Luke C, Schild A, Dinslage S, Krieglstein GK. Self-application of single-use eyedrop containers in an elderly population: comparisons with standard eyedrop bottle and with younger patients. Acta Ophthalmol. 2008;86:856-859.
8. Hiratani H, Mizutani Y, Alvarez-Lorenzo C. Controlling drug release from imprinted hydrogels by modifying the characteristics of the imprinted cavities. Macromol Biosci. 2005;5:728-733.
9. Mruthyunjaya P, Khalatbari D, Yang P, et al. Efficacy of lowrelease-rate fluocinolone acetonide intravitreal implants to treat experimental uveitis. Arch Ophthalmol. 2006;124:1012-1018.
10. Xu J, Li X, Sun F. Cyclodextrin-containing hydrogels for contact lenses as a platform for drug incorporation and release. Acta Biomater. 2010;6:486-493.
11. Xu J, Li X, Sun F. In vitro and in vivo evaluation of ketotifen fumarate-loaded silicone hydrogel contact lenses for ocular drug delivery. Drug Deliv. 2011;18:150-158.
12. Saettone MF, Giannaccini B, Chetoni P, Galli G, Chiellini E. Vehicle effects in ophthalmic bioavailability: an evaluation of polymeric inserts containing pilocarpine. J Pharm Pharmacol. 1984;36:229-234.
13. Urtti A, Rouhiainen H, Kaila T, Saano V. Controlled ocular timolol delivery: systemic absorption and intraocular pressure effects in humans. Pharm Res. 1994;11:1278-1282.
14. Andres-Guerrero V, Molina-Martinez IT, Peral A, de las Heras B, Pintor J, Herrero-Vanrell R. The use of mucoadhesive polymers to enhance the hypotensive effect of a melatonin analogue, 5-MCA-NAT, in rabbit eyes. Invest Ophthalmol Vis Sci. 2011;52: 1507-1515.
15. Gupta H, Aqil M, Khar RK, Ali A, Bhatnagar A, Mittal G. Biodegradable levofloxacin nanoparticles for sustained ocular drug delivery. J Drug Target. 2011;19:409-417.
16. Hao J, Fang X, Zhou Y, et al. Development and optimization of solid lipid nanoparticle formulation for ophthalmic delivery of chloramphenicol using a Box-Behnken design. Int J Nanomedicine. 2011;6:683-692.
17. Natarajan JV, Chattopadhyay S, Ang M, et al. Sustained release of an antiglaucoma drug: demonstration of efficacy of a liposomal formulation in the rabbit eye. PLoS One. 2011;6: e24513.
18. Zarbin MA, Montemagno C, Leary JF, Ritch R. Nanomedicine in ophthalmology: the new frontier. Am J Ophthalmol. 2010; 150:144-162. e142.
19. Fujie T, Okamura Y, Takeoka S. Ubiquitous transference of a free-standing polysaccharide nanosheet with the development of a nano-adhesive plaster. Adv Mater. 2007;19:3549-3553.
20. Takeoka S, Okamura Y, Fujie T, Fukui Y. Development of biodegradable nanosheets as nanoadhesive plaster. Pure Appl Chem. 2008;80:2259-2271.
21. Fujie T, Saito A, Kinoshita M, et al. Dual therapeutic action of antibiotic-loaded nanosheets for the treatment of gastrointestinal tissue defects. Biomaterials. 2010;31:6269-6278.
22. Cho J, Char K, Hong JD, Lee KB. Fabrication of highly ordered multilayer films using a spin self-assembly method. Adv Mater. 2001;13:1076-1078.
23. Jiang C, Markutsya S, Tsukruk VV. Compliant, robust, and truly nanoscale free-standing multilayer films fabricated using spinassisted layer-by-layer assembly. Adv Mater. 2004;16:157-161.
24. Nakano Y, Takahashi Y, Ono R, Kurata Y, Kagawa Y, Kamei C. Role of histamine H(4) receptor in allergic conjunctivitis in mice. Eur J Pharmacol. 2009;608:71-75.
25. Friedman DS, Quigley HA, Gelb L, et al. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS). Invest Ophthalmol Vis Sci. 2007;48:5052-5057.
26. Diebold Y, Calonge M. Applications of nanoparticles in ophthalmology. Prog Retin Eye Res. 2010;29:596-609.
27. Quigley HA. Glaucoma. Lancet. 2011;377:1367-1377.
28. Aihara M, Lindsey JD, Weinreb RN. Reduction of intraocular pressure in mouse eyes treated with latanoprost. Invest Ophthalmol Vis Sci. 2002;43:146-150.